Revance Therapeutics (STU:RTI) Asset Impairment Charge : €0.0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Asset Impairment Charge?

Revance Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2024 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was €0.0 Mil.

Revance Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Revance Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Asset Impairment Charge Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

65.88

85.45

Revance Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Revance Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Revance Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

RVNC:USA RTI:Germany

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines